

## VZV Replication Assays

Samantha J. Griffiths\* and Jürgen Haas

Division of Pathway and Infection Medicine, University of Edinburgh, Edinburgh, UK

\*For correspondence: [samantha.griffiths@ed.ac.uk](mailto:samantha.griffiths@ed.ac.uk)

**[Abstract]** Varicella zoster virus (VZV) is a human herpesvirus which causes Varicella (chickenpox) upon primary infection and Zoster (shingles) following reactivation from latency (von Bokay, 1909). Whilst VZV is extensively studied, inherent features of VZV replication, such as cell-association of virus particles during *in vitro* culture and a restricted host range (limited to humans and some other primates) mean the cellular and viral mechanisms underlying VZV reactivation and pathogenesis remain largely uncharacterised. Much remains to be learnt about VZV, interactions with its host, and the development of disease. This protocol describes a basic VZV replication assay using a recombinant VZV-GFP reporter virus. As VZV is highly cell-associated in tissue culture, the reporter virus inoculum described here is a preparation of infected cells. This reporter virus-infected cell line can be used in combination with siRNA gene depletion or cDNA overexpression transfection protocols to determine the effect of individual cellular genes on virus replication.

### Materials and Reagents

1. VZV-permissive human cells (e.g. MeWo cells) (ATCC, catalog number: HTB-65)
2. Minimal essential medium eagle with Earle's BBS, with L-glutamine (Lonza, catalog number: 12-611F)
3. Fetal bovine serum (FBS) (LabTech, catalog number: FCS-SA-10454)
4. Penicillin: streptomycin (5,000 units/ml each) (Lonza, catalog number: DE17-603E)
5. Non-essential amino acids (NEAA) (Life Technologies, catalog number: 11140035)
6. 1x Trypsin-EDTA liquid (0.05% Trypsin, 0.53 mM EDTA-4Na) (Life Technologies, catalog number: 25300096)
7. Phosphate buffered saline without Magnesium or Calcium (Lonza, catalog number: 17-516F)
8. Recombinant VZV-GFP cell-associated virus stock (Zerboni, 2000)
9. MeWo growth medium (see Recipes)

## **Equipment**

1. 75 cm<sup>2</sup> filter cap tissue culture flasks (Sigma-Aldrich, catalog number: C7106-120EA)
2. 96-well black tissue culture-treated plates (48/case) (VWR International, catalog number: 734-1609)
3. 50 ml centrifuge tube (e.g. Corning, catalog number: 430290)
4. Disposable hemocytometer (KOVA Glasstic slide 10 with counting grid) (HYCOR Biomedical, catalog number: 87144E)
5. Fluorescent plate reader (e.g. POLARstar OPTIMA, BMG LABTECH)
6. Class II Microbiological safety cabinet
7. Humidified cell culture incubator (37 °C, 5% CO<sub>2</sub>)
8. Pipette aid (Alpha laboratories, catalog number: 4-131-201-E)
9. Centrifuge (e.g. Eppendorf, catalog number: 5811-000.010)
10. Light microscope

## **Procedure**


1. Take a semi-confluent (~50%) T75 flask of MeWo cells that has been split the previous day (see Note 1).
2. Remove media, rinse gently in sterile phosphate buffered saline (PBS), and discard wash.
3. Dislodge cells by adding 3 ml trypsin. Incubate for around 5 min at 37 °C or until cells are fully dislodged.
4. Inactivate trypsin by adding 7 ml MeWo growth medium.
5. Pipette up and down to create a single-cell suspension.
6. Remove 12 µl and count cell density in a disposable hemocytometer.
7. Dilute cells to a density of 2 x 10<sup>5</sup> cells/ml in MeWo growth medium and seed 100 µl per well in a black, flat-bottomed 96-well plate to give 2 x 10<sup>4</sup> cells/well (see Note 2).
8. Leave cells to adhere overnight in a humidified incubator with 5% CO<sub>2</sub> at 37 °C.
9. Remove a vial of VZV-GFP of known titre from liquid nitrogen storage and thaw immediately in a water bath at 37 °C until just thawed (see Note 3).
10. Transfer thawed cells to a 50 ml centrifuge tube and slowly add 30 ml growth medium (pre-warmed to 37 °C) drop by drop to gradually increase the temperature of the cells.
11. Centrifuge for 10 min at 200 x g to pellet cells.
12. Gently remove the entire washing medium and resuspend in 1 ml growth media.
13. Dilute the cells in sufficient growth media to result in 1,000 IU/ml (see Note 4).

14. Remove plates from the incubator, and remove media by inverting plate and shaking over a container of suitable disinfectant.
15. Add 100 µl of the washed and resuspended VZV-GFP cell inoculum to each well to be infected, and 100 µl growth medium to uninfected control wells (see Note 5).
16. Replace the lid on the plate and return the plate back to the incubator. Monitor virus replication as a measure of GFP fluorescence from ~22 h post-infection until replication plateaus (see Note 6).
17. For comparison of virus replication in untreated and treated cells (protein overexpression, gene depletion, drug treatment *etc.*) calculate the replication slope over the linear growth phase and normalise treated cells to untreated ("normal" replication; Figure 1).

**A**

Hours post-infection	Relative Fluorescence		
	Mock	IDE	ORF28
41	4480	2808	1918
44	5392	3102	1981
47	6493	3496	2096
51	9503	4803	2592
54	11691	5755	2837
57	14466	6890	3002
60	17046	8175	3320
63	20169	9819	3802
66	23136	11395	4254
69	25139	12860	4732
72	27066	14821	5209
75	28460	17053	5945

**B**




**C**

Slope =  $\text{linest}(\text{known\_y's}, \text{known\_x's})$

	Mock	IDE	ORF28
Slope	878.8	414	107.7
Normalisation	$\text{=slope\_sample/slope\_control}$		
	$\text{=878.8/878.8}$	$\text{=414/878.8}$	$\text{=107.7/878.8}$
Normalised Slope	1.00	0.47	0.12

**D**



**Figure 1. Calculation of replication slopes.** A) Virus growth is monitored over multiple rounds of replication as a function of GFP fluorescence. B) Relative fluorescence units for mock transfected and positive controls-transfected (IDE, a cellular receptor for VZV; ORF28, the DNA polymerase for VZV) cells is plotted against hours post-infection to generate growth curve. C) The slope of replication over the linear phase of growth is calculated in Excel using the *linest* equation, and normalized to control (mock) transfected cells. D) Replication slopes are compared in a bar chart to see the effect of siRNA gene depletion on VZV replication.

## Notes

1. Virus replication proceeds more efficiently in cells that have been freshly passaged before seeding into assay plates.
2. Using a black assay plate will help reduce background and crosstalk between wells.
3. When grown in culture VZV virus particles remain associated with the cell membrane. As such, VZV-infected MeWo cells are used as the inoculum for VZV replication assays. These cells are stored in liquid nitrogen and need to be thawed and washed before use. Cells are extremely sensitive to temperature changes. When thawing it is essential that they are thawed quickly at 37 °C until only just thawed (1-2 min). Do not leave cells for longer periods of time as this will considerably reduce cell viability and therefore titre of replication-competent virus.
4. It is important to do the infection with a known quantity of virus (multiplicity of infection; MOI) to generate growth curve over a reasonable time-scale. The titre [number of infectious units per ml of virus (IU/ml)] of VZV-GFP-infected MeWo cells is determined by a standard plaque assay, where a virus stock is added to a Mewo cell monolayer and overlaid with agarose. This results in the infection only of adjacent cells, which subsequently die to leave an empty patch within the cell monolayer. These patches, or 'plaques' can be counted to quantify the virus as 'plaque-forming units', or infectious units (IU), per ml inoculum. In our experience 100 IU per well of a 96-well plate produces a suitable growth curve for replication analyses and comparisons. For example, a virus stock with a titre of  $6.6 \times 10^4$  IU/ml would contain 6,600 IU in 100  $\mu$ l. A 1 ml aliquot of virus inoculum should therefore be resuspended in 66 ml media.
5. Tissue culture plasticware, cells and growth medium all have some level of fluorescence. When utilising fluorescent reporter genes it is therefore essential to have appropriate controls to provide background fluorescence readings. For this assay, the fluorescence from mock-infected cells is used as background.
6. Replication is monitored over regular intervals to enable a complete growth curve (fluorescence over time) to be plotted. When comparing VZV replication between untreated and treated samples we use the slope of replication over the linear growth phase. It is therefore important to have as many measurements over this phase as possible (with a minimum of 6 for statistical reliability of the slope calculation). A test replication assay with your own equipment will allow the time of linear growth to be established, and assay timings can be adjusted to ensure measurements can be taken over this period.

## **Recipes**

1. MeWo growth medium  
Eagle's minimum essential medium (EMEM)  
5% FCS  
1% p-s  
1% NEAA

## **Acknowledgments**

We are grateful to Prof. Ann Arvin (Stanford School of Medicine) for the kind gift of the VZV-GFP clone, and to Dr. Armin Baiker for the propagation of a cell-associated VZV-GFP virus stock. The protocol was optimised by Dr Lakshmi N. Kaza and Dr Samantha Griffiths. The authors gratefully acknowledge the MRC for funding (G0501453 J.H.).

## **References**

1. von Bokay, J. (1909). Ueber den aetiologischen Zusammenhang der Varizellen mit gewissen Fällen von Herpes Zoster. *Wien Klin Wochenschr* 22: 1323-1326.
2. Zerboni, L., Sommer, M., Ware, C. F. and Arvin, A. M. (2000). [Varicella-zoster virus infection of a human CD4-positive T-cell line](#). *Virology* 270(2): 278-285.